The Drug Regulatory Authority of Pakistan (DRAP) has issued urgent alerts after laboratory testing identified five batches of counterfeit medicines in Karachi. The authority warned that using these products could pose serious health risks because their quality, safety and effectiveness remain unverified.
The affected medicines include Augmentin tablets, Velosef capsules, Nasomet nasal spray, No-Spa Forte 80mg tablets and Mucaine syrup. These products are commonly associated with treating bacterial infections, nasal allergies, muscle spasms and gastric irritation.
Laboratory Tests Confirm Counterfeit Medicines
According to the regulatory authority, the Drug Testing Laboratory in Karachi declared samples from all five batches counterfeit. The products allegedly entered the market illegally under the brand names of established national and multinational pharmaceutical companies.
Moreover, the authority stated that manufacturers had not verified or accepted the sampled products as genuine. Officials also found that they could not confirm the raw materials used in the medicines, leaving their safety and therapeutic effectiveness uncertain.
The findings have raised concerns about counterfeit medicines circulating through pharmaceutical supply chains. Such products may contain incorrect ingredients, inadequate quantities of active substances or potentially harmful materials.
Authorities Ordered to Seize Fake Medicine Batches
Following the laboratory findings, DRAP directed provincial drug control authorities and field teams to locate and seize the affected batches from pharmacies and other market outlets. The authorities must take prompt action to prevent further distribution and protect consumers from potential harm.
Additionally, healthcare professionals and medicine sellers should remain alert when handling the identified products. Consumers should check their medicines carefully and consult qualified pharmacists or healthcare professionals if they suspect a product may be counterfeit.
The alerts highlight the continuing challenges regulators face in preventing fake medicines from reaching patients. Effective inspections, laboratory testing and stronger supply-chain monitoring remain essential to ensuring that medicines meet required safety and quality standards.
DRAP has warned that using the counterfeit products could prove life-threatening and urged relevant authorities to act swiftly.
For the latest updates, visit and follow The Truth International website (www.thetruthinternational.com) and subscribe to the YouTube Channel.
